Janney Montgomery Scott LLC Sells 130 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Janney Montgomery Scott LLC decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,001 shares of the medical research company’s stock after selling 130 shares during the period. Janney Montgomery Scott LLC’s holdings in Bio-Rad Laboratories were worth $1,314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Van ECK Associates Corp increased its holdings in Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock valued at $436,861,000 after acquiring an additional 644,530 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at about $83,681,000. Wedge Capital Management L L P NC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth about $28,740,000. Mawer Investment Management Ltd. lifted its position in shares of Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after buying an additional 84,237 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Bio-Rad Laboratories by 38.3% during the third quarter. The Manufacturers Life Insurance Company now owns 86,782 shares of the medical research company’s stock valued at $29,036,000 after buying an additional 24,052 shares during the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $344.90 on Wednesday. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average price of $340.74 and a 200-day moving average price of $336.02. The firm has a market capitalization of $9.66 billion, a PE ratio of -12.62 and a beta of 0.90.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Citigroup increased their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.